Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure

被引:100
作者
Kuramoto, K
Ichikawa, S
Hirai, A
Kanada, S
Nakachi, T
Ogihara, T
机构
[1] Tokyo Metropolitan Geriatr Hosp, Itabashi Ku, Tokyo 1730015, Japan
[2] Cardiovasc Hosp Cent Japan, Gunma, Japan
[3] Chiba Prefectural Togane Hosp, Togane, Japan
[4] Osaka Clin Res Org Medicaments Clin, Suita, Osaka, Japan
[5] Tokyo Clin Res Org Medicaments Bld Clin, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
关键词
24-h blood pressure; pulse rate; pharmacokinetics; azelnidipine; amlodipine;
D O I
10.1291/hypres.26.201
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We objected: 1) To compare the effects of azelnidipine and amlodipine on 24-h blood pressure; 2) To monitor the plasma concentration vs. the time profile in order to assess the association between pharmacokinetics and hypotensive activity after administration of either drug for 6 weeks. Blood pressure and pulse rate were measured by 24-h monitoring with a portable automatic monitor in a randomized double-blind study of 46 patients with essential hypertension. Azelnidipine 16 mg (23 patients) or amlodipine 5 mg (23 patients) was administered once daily for 6 weeks. Pharmacokinetics were analyzed after the last dose was taken. Both drugs showed similar effects on the off ice blood pressure and pulse rate. During 24-h monitoring, both drugs caused a decrease in systolic blood pressure of 13 mmHg and had a similar hypotensive profile during the daytime period (07:00-21:30). The pulse rate decreased by 2 beats/min in the azelnidipine group, whereas it significantly increased by 4 beats/min in the amlodipine group. Similar trends in the blood pressure and pulse rate were observed during the nighttime (22:00-6:30) and over 24 h. Excessive blood pressure reduction during the nighttime was not seen in either group. The pharmacokinetic results indicated that the plasma half-life (tin) of amlodipine was 38.5+/-19.8 h and that of azelnidipine was 8.68+/-1.33 h. Despite this difference in pharmacokinetics, the hypotensive effects of amlodipine and azeinidipine were similar throughout the 24-h administration period.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 32 条
[21]  
NAKASHIMA M, 1991, J CLIN THER MED, V7, P1407
[22]   Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly: 1999 revised version [J].
Ogihara, T ;
Morimoto, S ;
Okaishi, K ;
Hiwada, K ;
Matsuoka, H ;
Matsumoto, M ;
Takishita, S ;
Shimamoto, K ;
Shimada, K ;
Abe, I ;
Kohara, K ;
Ouchi, Y .
HYPERTENSION RESEARCH, 2002, 25 (01) :69-75
[23]   ANTIHYPERTENSIVE EFFECTS OF CS-905, A NOVEL DIHYDROPYRIDINE CA++ CHANNEL BLOCKER [J].
OIZUMI, K ;
NISHINO, H ;
KOIKE, H ;
SADA, T ;
MIYAMOTO, M ;
KIMURA, T .
JAPANESE JOURNAL OF PHARMACOLOGY, 1989, 51 (01) :57-64
[24]   Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials [J].
Pahor, M ;
Psaty, BM ;
Alderman, MH ;
Applegate, WB ;
Williamson, JD ;
Cavazzini, C ;
Furberg, CD .
LANCET, 2000, 356 (9246) :1949-1954
[25]   THE RISK OF MYOCARDIAL-INFARCTION ASSOCIATED WITH ANTIHYPERTENSIVE DRUG THERAPIES [J].
PSATY, BM ;
HECKBERT, SR ;
KOEPSELL, TD ;
SISCOVICK, DS ;
RAGHUNATHAN, TE ;
WEISS, NS ;
ROSENDAAL, FR ;
LEMAITRE, RN ;
SMITH, NL ;
WAHL, PW ;
WAGNER, EH ;
FURBERG, CD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :620-625
[26]   Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension [J].
Sakata, K ;
Shirotani, M ;
Yoshida, H ;
Nawada, R ;
Obayashi, K ;
Togi, K ;
Miho, N .
HYPERTENSION, 1999, 33 (06) :1447-1452
[27]   Cardiovascular protection and blood pressure reduction: a meta-analysis [J].
Staessen, JA ;
Wang, YG ;
Thijs, L .
LANCET, 2001, 358 (9290) :1305-1315
[28]   Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [J].
Staessen, JA ;
Fagard, R ;
Thijs, L ;
Celis, H ;
Arabidze, GG ;
Birkenhager, WH ;
Bulpitt, CJ ;
deLeeuw, PW ;
Dollery, CT ;
Fletcher, AE ;
Forette, F ;
Leonetti, G ;
Nachev, C ;
OBrien, ET ;
Rosenfeld, J ;
Rodicio, JL ;
Tuomilehto, J ;
Zanchetti, A .
LANCET, 1997, 350 (9080) :757-764
[29]   MOLECULAR DETERMINANTS OF CA2+ CHANNEL FUNCTION AND DRUG-ACTION [J].
VARADI, G ;
MORI, Y ;
MIKALA, G ;
SCHWARTZ, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (02) :43-49
[30]  
YORAM Y, 1995, CARDIOVASC DRUG REV, V13, P137